Innate Pharma Stock Revenue
| IPHA Stock | USD 2.11 0.04 1.86% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Innate Pharma's long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 12.6 M | 12 M |
Innate | Revenue | Build AI portfolio with Innate Stock |
Innate Pharma Company Revenue Analysis
Innate Pharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Innate Pharma Revenue | 12.62 M |
Most of Innate Pharma's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innate Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Innate
Projected quarterly revenue analysis of Innate Pharma provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Innate Pharma match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Innate Pharma's stock price.
Innate Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Innate Pharma is extremely important. It helps to project a fair market value of Innate Stock properly, considering its historical fundamentals such as Revenue. Since Innate Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Innate Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Innate Pharma's interrelated accounts and indicators.
| 0.65 | 0.43 | -0.08 | 0.77 | 0.22 | ||
| 0.65 | 0.57 | -0.18 | 0.74 | 0.49 | ||
| 0.43 | 0.57 | -0.26 | 0.42 | 0.25 | ||
| -0.08 | -0.18 | -0.26 | -0.16 | -0.85 | ||
| 0.77 | 0.74 | 0.42 | -0.16 | 0.45 | ||
| 0.22 | 0.49 | 0.25 | -0.85 | 0.45 |
Click cells to compare fundamentals
Innate Revenue Historical Pattern
Today, most investors in Innate Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Innate Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Innate Pharma revenue as a starting point in their analysis.
Innate Pharma Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Innate Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Innate Pharma reported 12.62 M of revenue. This is 99.83% lower than that of the Biotechnology sector and 98.3% lower than that of the Health Care industry. The revenue for all United States stocks is 99.87% higher than that of the company.
Innate Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innate Pharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Innate Pharma could also be used in its relative valuation, which is a method of valuing Innate Pharma by comparing valuation metrics of similar companies.Innate Pharma is currently under evaluation in revenue category among its peers.
Innate Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Innate Pharma from analyzing Innate Pharma's financial statements. These drivers represent accounts that assess Innate Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Innate Pharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 21.1B | 353.8M | 262.0M | 210.8M | 189.7M | 180.2M | |
| Enterprise Value | 21.0B | 294.3M | 220.0M | 180.1M | 162.1M | 154.0M |
Innate Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Innate Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Innate Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Innate Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Innate Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Innate Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Innate Pharma's value.| Shares | Exchange Traded Concepts, Llc | 2025-03-31 | 62.8 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 43.5 K | Citadel Advisors Llc | 3025-03-31 | 24.3 K | Millennium Management Llc | 2025-03-31 | 15.3 K | Ubs Group Ag | 2025-03-31 | 9 K | Gamma Investing Llc | 2025-06-30 | 3.5 K | Rhumbline Advisers | 2025-03-31 | 675 | Barclays Plc | 2025-03-31 | 307 | Optiver Holding B.v. | 2025-03-31 | 101 | Tower Research Capital Llc | 2025-03-31 | 3.0 | Steward Partners Investment Advisory, Llc | 2025-03-31 | 0.0 |
Innate Fundamentals
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (2.46) % | ||||
| Operating Margin | (3.25) % | ||||
| Current Valuation | 138.54 M | ||||
| Shares Outstanding | 92.16 M | ||||
| Shares Owned By Institutions | 0.17 % | ||||
| Number Of Shares Shorted | 52.01 K | ||||
| Price To Book | 19.63 X | ||||
| Price To Sales | 9.85 X | ||||
| Revenue | 12.62 M | ||||
| Gross Profit | (31.86 M) | ||||
| EBITDA | (46.91 M) | ||||
| Net Income | (49.47 M) | ||||
| Cash And Equivalents | 123.35 M | ||||
| Cash Per Share | 1.54 X | ||||
| Total Debt | 31 M | ||||
| Debt To Equity | 0.37 % | ||||
| Current Ratio | 2.34 X | ||||
| Book Value Per Share | 0.10 X | ||||
| Cash Flow From Operations | (6.9 M) | ||||
| Short Ratio | 4.88 X | ||||
| Earnings Per Share | (0.70) X | ||||
| Target Price | 7.89 | ||||
| Number Of Employees | 181 | ||||
| Beta | 0.96 | ||||
| Market Capitalization | 198.15 M | ||||
| Total Asset | 111.06 M | ||||
| Retained Earnings | (386.36 M) | ||||
| Working Capital | 52.76 M | ||||
| Net Asset | 111.06 M |
About Innate Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innate Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innate Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innate Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Innate Pharma Piotroski F Score and Innate Pharma Altman Z Score analysis. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.70) | Revenue Per Share | Quarterly Revenue Growth (0.64) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.